COVID-19: Multiorgan Dissemination of SARS-CoV-2 Is Driven by Pulmonary Factorsстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 4 марта 2022 г.
Аннотация:Multi-organ failure is one of the common causes of fatal outcome in COVID-19 patients.However, the pathogenetic association of the SARS-CoV-2 viral load (VL) level with fatal dysfunctions of the lungs, liver, kidneys, heart, spleen and brain, as well as with the risk of death in COVID-19 patients remains poorly understood. SARS-CoV-2 VL in the lungs, heart, liver, kidneys,brain, spleen and lymph nodes have been measured by RT qPCR using the following formula:NSARS-CoV−2/NABL1 × 100. Dissemination of SARS-CoV-2 in 30.5% of cases was mono-organ, and in 63.9% of cases, it was multi-organ. The average SARS-CoV-2 VL in the exudative phase of diffusealveolar damage (DAD) was 60 times higher than in the proliferative phase. The SARS-CoV-2 VLin the lungs ranged from 0 to 250,281 copies. The “pulmonary factors” of SARS-CoV-2 multi-organdissemination are the high level of SARS-CoV-2 VL (≥4909) and the exudative phase of DAD. Thefrequency of SARS-CoV-2 dissemination to lymph nodes was 86.9%, heart–56.5%, spleen–52.2%,liver–47.8%, kidney–26%, and brain–13%. We found no link between the SARS-CoV-2 VL level inthe liver, kidneys, and heart and the serum level of CPK, LDH, ALP, ALT, AST and Cr of COVID-19patients. Isolated detection of SARS-CoV-2 RNA in the myocardium of COVID-19 patients who diedfrom heart failure is possible. The pathogenesis of COVID-19-associated multi-organ failure requires further research in a larger cohort of patients.Keywords: COVID-19; SARS-CoV-2; multiplex real-time polymerase chain reaction; viral load; FFPE;multi-organ dissemination